Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

Semaglutide is sold by Novo Nordisk as Ozempic for treatment of type 2 diabetes and as Wegovy for weight management. It ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

By KENYA HUNTER The majority of strokes could be prevented, according to new guidelines aimed at helping people and their ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

In general, when a person prepares for a surgery, the guidance is to fast before going under anesthesia– but for patients, on gGLP-1's there may still be gastric juices, in the stomach, since the ...

Slickly designed websites. Unbelievable markdowns. A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

The national use of weight loss drugs like Ozempic and Wegovy more than doubled as bariatric surgery frequency dropped by ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...